End-of-day quote
Shanghai S.E.
06:00:00 2024-07-14 pm EDT
|
5-day change
|
1st Jan Change
|
16.99
CNY
|
-0.18%
|
|
-1.96%
|
-18.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,165
|
6,559
|
8,379
|
10,707
|
15,812
|
12,863
|
-
|
-
|
Enterprise Value (EV)
1 |
8,165
|
6,559
|
8,379
|
10,707
|
15,812
|
12,863
|
12,863
|
12,863
|
P/E ratio
|
18
x
|
14.4
x
|
16.5
x
|
27.7
x
|
35.4
x
|
21.3
x
|
16.5
x
|
13.5
x
|
Yield
|
-
|
-
|
-
|
-
|
0.96%
|
-
|
1.06%
|
-
|
Capitalization / Revenue
|
1.01
x
|
0.85
x
|
1.02
x
|
1.29
x
|
2.05
x
|
1.49
x
|
1.29
x
|
1.17
x
|
EV / Revenue
|
1.01
x
|
0.85
x
|
1.02
x
|
1.29
x
|
2.05
x
|
1.49
x
|
1.29
x
|
1.17
x
|
EV / EBITDA
|
-
|
9.2
x
|
10.4
x
|
15
x
|
21.1
x
|
13.3
x
|
10.8
x
|
9.14
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
1.47
x
|
1.75
x
|
2.15
x
|
2.98
x
|
2.21
x
|
1.99
x
|
1.77
x
|
Nbr of stocks (in thousands)
|
760,948
|
758,256
|
758,256
|
758,256
|
757,987
|
757,114
|
-
|
-
|
Reference price
2 |
10.73
|
8.650
|
11.05
|
14.12
|
20.86
|
16.99
|
16.99
|
16.99
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,120
|
7,717
|
8,254
|
8,282
|
7,703
|
8,611
|
9,985
|
11,004
|
EBITDA
1 |
-
|
712.9
|
806.8
|
713.2
|
749.2
|
969.1
|
1,188
|
1,408
|
EBIT
1 |
-
|
540.8
|
634
|
497.1
|
568.5
|
782.7
|
1,008
|
1,244
|
Operating Margin
|
-
|
7.01%
|
7.68%
|
6%
|
7.38%
|
9.09%
|
10.1%
|
11.3%
|
Earnings before Tax (EBT)
1 |
-
|
540.5
|
631.3
|
477.3
|
563.6
|
774.8
|
1,002
|
1,236
|
Net income
1 |
-
|
456.9
|
507.7
|
383.2
|
444.7
|
601.3
|
778.4
|
950.9
|
Net margin
|
-
|
5.92%
|
6.15%
|
4.63%
|
5.77%
|
6.98%
|
7.8%
|
8.64%
|
EPS
2 |
0.5965
|
0.6018
|
0.6695
|
0.5100
|
0.5900
|
0.7960
|
1.028
|
1.258
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
0.2000
|
-
|
0.1800
|
-
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
10.6%
|
11%
|
7.89%
|
8.64%
|
10.3%
|
12%
|
13.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
4.68%
|
5.9%
|
6.94%
|
7.2%
|
Assets
1 |
-
|
-
|
-
|
-
|
9,499
|
10,191
|
11,216
|
13,207
|
Book Value Per Share
2 |
-
|
5.870
|
6.310
|
6.570
|
6.990
|
7.680
|
8.540
|
9.590
|
Cash Flow per Share
2 |
-
|
0.5400
|
0.3300
|
0.3300
|
0.4700
|
0.9500
|
1.050
|
1.350
|
Capex
1 |
-
|
46.6
|
226
|
65.5
|
57.1
|
109
|
144
|
122
|
Capex / Sales
|
-
|
0.6%
|
2.74%
|
0.79%
|
0.74%
|
1.27%
|
1.45%
|
1.11%
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
16.99
CNY Average target price
25.01
CNY Spread / Average Target +47.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.55% | 1.78B | | +63.05% | 854B | | +39.42% | 636B | | -4.78% | 361B | | +17.52% | 324B | | +8.43% | 301B | | +14.19% | 247B | | +5.81% | 230B | | +16.77% | 228B | | +14.63% | 177B |
Other Pharmaceuticals
|